<DOC>
	<DOCNO>NCT00647114</DOCNO>
	<brief_summary>Treatment patient cancer type know express HER-2 and/or CEA tumor antigen .</brief_summary>
	<brief_title>A Study Test V930/V932 Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 ( HER-2 ) and/or Carcinoembryonic Antigen ( CEA ) ( V930-003 ) ( COMPLETED )</brief_title>
	<detailed_description>The optional followup period study 1 year last vaccination .</detailed_description>
	<criteria>Patients must complete surgical treatment his/her primary disease least 1 month prior enrollment Patient must pregnant 3 day prior enrollment Patient currently participate participate study investigational compound device within 30 day sign informed consent Patient spleen remove history autoimmune disorder Patient regular user illicit drug use within past year drug alcohol abuse Patient pregnant breastfeeding expect conceive anytime follow study Patient know Human Immunodeficiency Virus ( HIV ) seropositive Patient know history Hepatitis B C Patient receive vaccine disease condition within one month enrollment Patient primary central nervous system tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Cancers express HER-2 and/or CEA</keyword>
</DOC>